公司概述
PRF Technologies Ltd. operates as a clinical-stage specialty pharmaceutical entity dedicated to the reformulation of established therapeutics to provide extended post-surgical pain relief specifically within the Israeli market. The company functions within the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry, a classification that signifies its focus on specialized medicinal products rather than mass-market commodities. In terms of scale, the enterprise holds a market capitalization of $1.98M and reported total revenue of $17,000 over the trailing twelve-month period, while the number of employees is listed as N/A. These valuation and revenue figures indicate that the company operates at a very small scale, suggesting it is an early-stage venture with limited market penetration and minimal operational footprint relative to larger pharmaceutical peers.
财务健康
The company reported revenue of $17,000 for the trailing twelve months, yet recorded a net income of -$4,838,000, a significant disparity that reveals an extremely fragile cost structure where operating expenses vastly outweigh revenue generation. Additionally, the EBITDA stood at -$4,348,000, further highlighting the heavy burn rate typical of clinical-stage development efforts before product commercialization scales up. Free cash flow was -$2,002,250, which indicates that the company is currently consuming cash reserves to fund operations and research rather than generating liquidity for distribution or debt repayment. The gross margin is 0.0%, the operating margin is -16200.0%, and the profit margin is 0.0%, collectively indicating that the business model has not yet achieved profitability or cost efficiency at the current revenue level. On the balance sheet, the company holds $4.14M in cash against $21,000 in debt, resulting in a debt-to-equity ratio of 0.23, which suggests a highly conservative capital structure with negligible leverage despite the cash burn. The current ratio of 1.78 indicates that the company possesses sufficient liquid assets to cover its short-term liabilities with a margin of safety above the standard 1.0 threshold. Return on Equity is -90.4% and Return on Assets is -38.7%, metrics that reveal management is currently destroying shareholder value and utilizing assets inefficiently in the context of generating immediate financial returns.
估值评估
The trailing P/E ratio is N/A due to negative earnings, while the forward P/E is -0.19, a metric that implies the market is pricing in future profitability that has not yet materialized in the current financial statements. The price-to-book ratio stands at 0.23, indicating that the market values the company at significantly less than the replacement cost of its underlying assets, reflecting high risk perception. The price-to-sales ratio is 116.25 and the EV/EBITDA is 0.32, suggesting that the valuation is heavily dependent on revenue multiples rather than earnings power, which is common for pre-revenue or loss-making biotech firms. The stock has traded between a 52-week low of $1.80 and a 52-week high of $17.95, placing the current market price contextually within a highly volatile historical range where the equity has experienced substantial fluctuation. The beta value of 0.71 indicates that the stock's price volatility is lower than the broader market, suggesting it may be less sensitive to general market movements despite its high risk profile.
Growth & Income
The revenue growth year-over-year is N/A and earnings growth year-over-year is N/A, which precludes any assessment of whether earnings are growing faster or slower than revenue due to the lack of comparable historical data points. As the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, meaning the company retains all of its negative earnings to fund its clinical development pipeline rather than distributing income to shareholders. Since the entity does not pay dividends, it is clear that the firm reinvests its limited resources and existing cash reserves into growth initiatives such as drug formulation and regulatory approval processes rather than providing income returns. Consequently, the overall growth and income profile is characterized by a complete reliance on capital markets for funding and an absence of current income generation or historical earnings growth metrics.